Mode
Text Size
Log in / Sign up
Phase 2 Completed N=30 Randomized Triple-blind Treatment

Varenicline for Smoking Cessation in Heavy Drinking Smokers

Nicotine Dependence · Smoking · Heavy Drinking
Source: ClinicalTrials.gov NCT00860028 ↗
Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Mar 2013
Primary outcomePrimary: Number of Participants Reporting Continuous Smoking Abstinence in the Extended Varenicline Pretreatment Versus Short-term Varenicline Pretreatment Conditions. — 4; 2 Participants — p=0.36

Summary

The purpose of this study is to determine whether extended pretreatment with varenicline (Chantix) is more efficacious for smoking cessation than standard pretreatment, how well varenicline is tolerated in heavy drinking smokers, and whether varenicline reduces alcohol consumption.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Reporting Continuous Smoking Abstinence in the Extended Varenicline Pretreatment Versus Short-term Varenicline Pretreatment Conditions.
4; 2 0.36
PRIMARY
Mean Percentage of Heavy Drinking Days Comparing Participants in the Extended Varenicline Pretreatment Versus Short-term Varenicline Pretreatment Conditions
22.7; 38.0 0.06
SECONDARY
Number of Participants Who Reported an Adverse Event in the Varenicline Pretreatment Versus Placebo Pretreatment Conditions
10; 3 0.03 sig

Eligibility Criteria

Inclusion Criteria

  • Between the ages of 18 and 75.
  • Smoking 5 or more cigarettes per occasion at least 3 times per week.
  • Fewer than 3 months of smoking abstinence in the past year.
  • Motivated to stop smoking.
  • Report exceeding maximum weekly drinking limits every week in the past 4 weeks and exceeding maximum daily drinking limits on at least 1 occasion in the past 4 weeks. Weekly heavy drinking is defined as 8 or more drinks for women and 15 or more drinks for men. Daily heavy drinking is defined as 4 or more drinks for women and 5 or more drinks for men on an occasion.

Exclusion Criteria

  • Exhibit current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation
  • Any unexplained elevations in liver enzymes (i.e., transaminases, bilirubin)
  • Clinically significant cardiovascular disease
  • Uncontrolled hypertension
  • Hepatic or renal impairment
  • Severe chronic obstructive pulmonary disease
  • Diabetes mellitus requiring insulin or oral hypoglycemic medications.
  • Baseline systolic blood pressure higher than 150 mm Hg or diastolic blood pressure higher than 95 mm Hg
  • History of cancer (except treated basal cell or squamous cell carcinoma of the skin).
  • History of clinically significant allergic reactions.
  • Exhibit serious psychiatric illness (i.e., schizophrenia, bipolar disorder, severe major depression, panic disorder, borderline personality disorder, organic mood or mental disorders, or substantial suicide or violence risk) by history or psychological examination)
  • Have a current diagnosis of DSM-IV drug dependence other than nicotine or alcohol.
  • Have a current Diagnostic and Statistical Manual Diploma in Social Medicine IV (DSM-IV) diagnosis of alcohol dependence that is clinically severe defined by a) a history of seizures, delirium, or hallucinations during alcohol withdrawal, b) a Clinical Institute Withdrawal Assessment scale (Sullivan et al., 1989) score of > 8, c) report drinking to avoid withdrawal symptoms, or d) have had prior treatment of withdrawal.
  • Use of another investigational drug within 30 days.
  • Intention to donate blood or blood products during the treatment phase of the study.
  • Use of tobacco products other than cigarettes or use of marijuana.
  • Use of nicotine replacement therapy, clonidine, varenicline, bupropion, or nortriptyline within the month prior to enrollment or intention to use medication that might interfere with study medication.
  • Body Mass Index (calculated as weight in kilograms divided by the square of height in meters) less than 15 or greater than 38 or weight less than 45 kg.
  • Females of childbearing potential who are pregnant, nursing, or not practicing effective contraception (oral, injectable, or implantable contraceptives, intrauterine device, or barrier method with spermicide).
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00860028). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search